Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection15-04-2023
15-04-2023
Zydus Lifesciences Ltd - 532321 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Certificate under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 202313-04-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201511-04-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Tavaborole Topical Solution, 5%11-04-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Azithromycin Tablets USP, 500 mg10-04-2023
Zydus Lifesciences Ltd - 532321 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyZydus Lifesciences Ltd 2CIN NO.L24230GJ1995PLC025878 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhaval N Soni Designation: Company Secretary EmailId: dhavalsoni@zyduslife.com Name of the Chief Financial Officer: Nitin D Parekh Designation: Chief Financial Officer EmailId: nitinparekh@zyduslife.com Date: 06/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.06-04-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
(1) 'Zydus receives final approval from the USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg' and (2) 'Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg'06-04-2023
Zydus Lifesciences Ltd - 532321 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On March 31, 2023
Certificate under regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 202305-04-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on March 31, 202305-04-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201529-03-2023